Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash & Equivalents (2016 - 2025)

Apyx Medical (APYX) has disclosed Cash & Equivalents for 16 consecutive years, with $31.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents changed 0.13% year-over-year to $31.7 million, compared with a TTM value of $31.7 million through Dec 2025, changed 0.13%, and an annual FY2025 reading of $31.7 million, changed 0.13% over the prior year.
  • Cash & Equivalents was $31.7 million for Q4 2025 at Apyx Medical, up from $25.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $43.7 million in Q4 2023 and bottomed at $10.2 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $27.7 million, with a median of $30.1 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 66.98% in 2022, then skyrocketed 328.3% in 2023.
  • Year by year, Cash & Equivalents stood at $30.9 million in 2021, then tumbled by 66.98% to $10.2 million in 2022, then surged by 328.3% to $43.7 million in 2023, then dropped by 27.29% to $31.7 million in 2024, then dropped by 0.13% to $31.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for APYX at $31.7 million in Q4 2025, $25.1 million in Q3 2025, and $29.3 million in Q2 2025.